Dear Na Ma, EIC, and reviewer:

Thank you so much for your kind invitation for re-submitting our manuscript No. 56477, entitled "Stem Cell Therapy for COVID-19 and Other Respiratory Diseases: Global Trends of Clinical Trials". Please find our point-by-point responses below.

Reviewer #1:

Scientific Quality: Grade A (Excellent)

Language Quality: Grade A (Priority publishing)

Conclusion: Accept (High priority)

Specific Comments to Authors: First, the original finding of this manuscript is a potential use of stem cell therapy in COVID-19. the new hypotheses that this study is that we can focused on stem cell therapy because it can be a best therapy with lowest side effects. the new phenomena that were found through experiments in this study are all clinical details in stem cell therapy in covid-19. the hypotheses that were confirmed through experiments in this study is stem cell therapy in lung destruction diseases. Second the quality and importance of this manuscript is excellent, the new findings of this study is to be cover of practical use of stem cell in covid-19, the new methods that this study proposed are release to all practical procedures to it usage, the conclusions appropriately summarize the data that this study provided are best, the unique insights that this study presented, the key problems in this field that this study has solved is stem cell therapy method in covid-19 therapy. Third, the limitations of the study are clinical trial procedures in all stage over 3, the future directions of the topic described in this manuscript is good, the questions/issues that remain to be solved its completely trial in clinical forms and details. This report can be a impressive impact to change of covid-19 therapeutic procedures in all of world.

Response: We thanks the reviewer for his/her extremely positive tone of our mini-review.

Editorial Office's comments

(1) Science Editor: 1 Scientific quality: The manuscript describes a minireviews of the stem cell therapy for COVID-19 and other respiratory diseases. The topic is within the scope of the WJSC. (1) Classification: Grade A; (2) Summary of the Peer-Review Report: The authors reported the global trends of clinical trials of stem cell therapy for COVID-19 and other respiratory diseases. The quality and importance of this manuscript is excellent; and (3) Format: There are 2 figures and 1 table. A total of 69 references are cited, including 28 references published in the last 3 years. There are no self-citations. 2 Language evaluation: Classification: Grade A. **The author is the English native speaker**. 3 Academic norms and rules: The authors provided the signed Conflict-of-Interest Disclosure Form and Copyright License Agreement. No academic misconduct was found in the CrossCheck detection and Bing search. 4 Supplementary comments: This is an **invited manuscript**. The study was supported by 1 NIH grant. The topic has not previously been published in the WJSC. 5 Issues raised: (1) The authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy of any approval document(s); (2) The authors did not provide original pictures. Please

provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor; and (3) PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout. 6 Re-Review: Required. 7 Recommendation: Conditional acceptance.

Response: To address three issues raised by the Science Editor, 1) we have included the Notice of Award for our NIH grant. 2) We have uploaded Powerpoint files for two figures. 3) PMID and DOI have been added to all references except the last reference published in the bioRxiv that does not have a PMID.

- (2) Editorial Office Director: I have checked the comments written by the science editor.
- (3) *Company Editor-in-Chief*: I have reviewed the Peer-Review Report, the full text of the manuscript and the relevant ethics documents, all of which have met the basic publishing requirements, and the manuscript is conditionally accepted with minor revisions. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report and the Criteria for Manuscript Revision by Authors.

Again, thank you so very much for your kind comments of the editorial team.

Sincerely,

James Ji

On behalf of other authors